NCT02206100View on ClinicalTrials.gov

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

PER977

reversal of edoxaban-induced anticoagulation

DRUG

Placebo

Reversal of edoxaban-induced anticoagulation

DRUG

enoxaparin

Trial Locations (1)

66211

Quintiles, Overland Park

All Listed Sponsors
lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT02206100 - PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin | Biotech Hunter | Biotech Hunter